MASCC Antiemetics Study Group
Guidelines & Assessment Tools
FDA Approves Rolapitant for Chemotherapy-Induced Nausea and Vomiting
FDA and EU Commission Approval for Netupitant/Palonosetron (Akynzeo)
History and Purpose
The Antiemetic Study Group was originally established as a subcommittee of MASCC to address the control of nausea and vomiting induced by chemotherapy and radiotherapy. At the 1995 MASCC Annual Meeting in Luxembourg, the group organized a consensus conference on the use of antiemetics. To identify the most important topics on which consensus should be measured and developed, the group constructed a questionnaire and circulated it to experts. The results, published in Supportive Care in Cancer, identified eight major issues that served as the basis for the conference (Ballatori et al, Support Care Cancer 1997; 5: 269-273). The Consensus Conference was held in Perugia, Italy, 28-29 April 1997, and results were published in the ESMO journal, Annals of Oncology (Ann Oncol.1998; 9: 811-819).
In the following years, the Study Group has worked in two directions. First, because various guideline recommendations for antiemetic prophylaxis (from, for example, the ASCO, ESMO, MASCC, NCON, and ASHP) differed, a unified consensus conference was held in New York. 19-20 April 2001. The final document of the conference was presented during the ASCO-MASCC Joint Session held in San Francisco, 14 May, 2001.
Second, the members of the Study Group have always been most concerned about the moderate transfer of knowledge from clinical trials to clinical practice. The Study Group thus planned an international drug utilization study to study antiemetic prescriptions and effectiveness with respect to delayed emesis induced by chemotherapy. Despite optimal prophylaxis, this remains one of the unsolved problems of antiemetic therapy.
A Guide to Oncology Symptom Management
Books on Supportive Care >>VIEW ALL - MASCC Member Discounts
Past Workshop - MASCC/ISOO Annual Meeting
Issues in Controlling Nausea Associated with Cancer Chemotherapy. Athens, 2011 >> Read More
MASCC Endorsed Guideline Partnerships
*Disclaimer* The evidence used in formulating this guideline was rated as "low level" by the authors and much of it was derived from evidence in the adult population, rather than a pediatric population. While the conclusions have face validity, the strength of the recommendations is limited by a dearth of high-quality data. There remains a need for more studies in the pediatric population.
Acute AINV Guideline for Pediatric Cancer Patients
Please contact the Study Group Chairs above with your questions.